#108 MDIPN-ISOPROPYL-MDA; (3,4-METHYLENEDIOXY-N-ISOPROPYLAMPHETAMINE)
|[3D .mol structure]|
DOSAGE: greater than 250 mg.
QUALITATIVE COMMENTS: (with 250 mg) At 35 minutes there was an extremely slight head disturbance which increased over the next few minutes. I would have missed it if there had been any sensory input at all. At the one hour point there was a slight physical malaise, but no 'open window' of any kind, either like MDMA or like LSD. At the most, this was a threshold, and in another half hour, I was completely baseline.
EXTENSIONS AND COMMENTARY: The structure of MDIP can be looked at as exactly that of MDE but with an additional methyl group (one carbon) hanging off the ethyl that is on the nitrogen. And with that slight additional weight, the activity has disappeared. On those occasions where research has shown a compound to be inactive, there has been some study made that could be called a "primer" experiment. Why not take advantage of the fact that an "inactive" compound might well be sitting in some receptor site in the brain without doing anything? Might its presence, wherever it might be, have some effect if only a person were to explore it in the correct way? Might it augment or interfere with the action of another compound? Many experiments of this kind have been performed, geared to milk additional information out of a new trial of a new material.
Here is an example of a primer experiment that involved MDIP. Some five hours following an inactive trial with 120 milligrams of MDIP (maybe a slight disturbance at one hour, nothing at two hours) a calibration dose of 80 milligrams of MDMA was taken. The effects of the MDMA were noted at the 33 minute point, and an honest plus one was achieved at one hour. At this point a second 80 milligrams was added to the inventory that was already on board, and the general intoxication and the eye effects that followed were completely explained by the MDMA alone. It was obvious that the two drugs did not see one-another.
Sometimes an experiment can involve the assay of an unknown material at the supplement time of an active drug. This has been called "piggybacking." Here is an example. At the five hour point of an experiment with 140 milligrams of MDE (this had been a light experience, a plus one which had not laster more than two hours) a dosage of 200 milligrams of MDIP rekindled a +1 experience, a pleasant intoxication of the MDE sort, but one that was quite invested with tremor and some feelings of eye-popping. It was almost as if the physical toxic effects outweighed the mental virtues. Imagine an iceberg, with the bulk of its mass underwater. The MDE had had its own modest effects, and had submerged into invisibility, and the response to a little bit of an otherwise inactive MDIP was to refloat a bit of the otherwise unseeable MDE.
|[ Back]||[Main Index]||[Forward ]|